ImportantUpdates

Windlas Biotech's Codeine cough syrup production is temporarily suspended after a Show Cause Notice from drug authorities.

Windlas Biotech Limited logo
Windlas Biotech LimitedWINDLAS · Filed with the exchange

This product line contributed Rs. 55.21 Cr to current FY revenue.

Only Codeine-based syrups are affected; other production continues normally.

Read the original filing(PDF)

No comments yet. Be the first.

More from Windlas Biotech Limited

All announcements